ARCA biopharma to receive US patent for methods of heart failure treatment with genetic testing based bucindolol

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting.” The Notice of Allowance is the USPTO’s official communication that the examination of the patent application has been successfully completed and that a patent will be issued. Once issued, the patent will provide coverage for methods of treating heart failure patients with bucindolol based on genetic testing.

“This allowance and anticipated issuance of the patent highlight ARCA’s belief in, and commitment to, developing genetically targeted therapies for the treatment of heart failure and other cardiovascular diseases.”

“We are very pleased with the USPTO’s decision to grant this patent which extends our pharmacogenetic intellectual property protection around bucindolol in to 2025,” said Michael R. Bristow, President and Chief Executive Officer of ARCA. “This allowance and anticipated issuance of the patent highlight ARCA’s belief in, and commitment to, developing genetically targeted therapies for the treatment of heart failure and other cardiovascular diseases."